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ABSTRACT
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder caused by a somatic mutation of the
X-linked phosphatidylinositol glycan class A gene. Allogeneic hematopoietic cell transplantation (HCT) after
high-dose conditioning is the only curative treatment; however, it is associated with high treatment-related
mortality. Here, we report on allogeneic HCT for PNH after minimal conditioning. Seven adult patients with
high-risk PNH underwent peripheral blood HCT from HLA-A–, -B–, -C–, -DRB1–, and -DQB1–matched
related (n  2) and unrelated (n  5) donors. Conditioning included fludarabine 30 mg/m2/d on days 4 to 2
and 2 Gy of total body irradiation on day 0. After HCT, patients were given immunosuppressive therapy with
oral cyclosporine starting on day 3 and mycophenolate mofetil starting on day 0. All 7 patients attained
durable engraftment. After 28 days, a median of 77% (range, 53%-96%) T-cell donor chimerism was found in
bone marrow and peripheral blood. T-cell chimerism increased to 91% (range, 76%-100%) on day 180 and
to 100% in all surviving patients after 12 months. All 7 patients attained complete remissions of their disease.
Four patients are alive 13 to 38 months after HCT. Three patients died of treatment-related mortality, 1
because of complications after acute pancreatitis and multiorgan failure, 1 because of infection related to
chronic graft-versus-host disease (GVHD), and 1 because of bleeding after liver biopsy for late subacute/
chronic GVHD. Allogeneic HCT from related and unrelated donors after minimal conditioning is a new and
potentially curative option for patients with advanced PNH.
© 2003 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a
lonal disease of hematopoiesis caused by a mutation
n the X-linked phosphatidylinositol glycan class A
ene. The mutation results in defective synthesis of
he glycosylphosphatidylinositol (GPI) anchor re-
uired for the attachment of a number of proteins to
he cell surface [1,2]. Deﬁciency of one of the pro-
eins, known as the membrane inhibitor of reactive a
B&MTysis (CD59), is responsible for the hemolysis and is
mplicated in the pathogenetic mechanisms of throm-
otic complications. Flow cytometric and polymerase
hain reaction techniques are used today to detect the
ack of this and other PNH-speciﬁc proteins. These
echniques conﬁrm the diagnosis of PNH and replace
he diagnostic Ham’s test developed in the late 1930s.
NH has been reported in association with severeParoxysmal nocturnal hemoglobinuria
oi:10.1016/S1083-8791(03)00264-7eneic HCTplastic anemia, myelodysplastic syndromes (MDS),
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myeloproliferative disorders, and acute leukemia [3].
At the time of diagnosis, 90% of patients have periph-
eral blood cell abnormalities. In the course of their
disease, patients may develop hemolysis and venous
thrombosis. The venous thrombosis may involve al-
most any organ or site and is the leading cause of
death. Other complications, such as hepatitis or
hemochromatosis, are often treatment related.
The clinical course of PNH is usually chronic, and
survival ranges from a few months to many years
(median of approximately 10 years) [4]. In a multivar-
iate analysis, various factors—such as thrombocytope-
nia at diagnosis, progression to thrombocytopenia,
development of thrombosis, pancytopenia, MDS or
acute leukemia, and age55 years—were identiﬁed as
negative risk factors for survival [4,5]. Patients with
thrombocytopenia at diagnosis and development of
thrombosis were at 1.4 and 9.4 times higher risk of
dying from PNH, respectively, than were patients
without these risk factors. In patients with such risk
factors, survival is restricted to a few months.
Despite remarkable progress in understanding
the pathogenesis, treatment options in PNH have
remained supportive or are directed at immune
modulation. These include red blood cell (RBC)
transfusions, immunosuppressive therapy, or both. Al-
logeneic hematopoietic cell transplantation (HCT) af-
ter high-dose conditioning regimens is the only cur-
ative therapy currently available; however, it is
associated with considerable morbidity and mortality
[6-14]. Most grafts have involved related donors, with
only 12 cases of HCT from unrelated donors reported
to date. Recent years have seen the development of
HCT with reduced-intensity conditioning regimens
in patients with hematologic diseases at high risk of
treatment-related mortality [15-20]. Here, we de-
scribe the use of minimal-intensity conditioning,
which was originally developed in a canine model
[17,18] and was then used to treat patients with he-
matologic malignancies not eligible for high-dose
conventional HCT [19,20]. The regimen consists of
host immunosuppression with 3 doses of ﬂudarabine
(30 mg/m2/d  3) and a single dose of 2 Gy of total
body irradiation (TBI) before HCT. For control of
both engraftment and graft-versus-host disease
(GVHD), a novel, synergistic combination of the im-
munosuppressive drugs mycophenolate mofetil
(MMF) and cyclosporine (CSP) has been used after
HCT. This study reports on HCT from HLA-
matched related (n  2) and unrelated (n  5) donors
in 7 patients with high-risk PNH.
PATIENTS AND METHODS
Seven patients underwent transplantation from
October 1999 to November 2001 at the University
Hospital of Leipzig (n  3) and Regensburg (n  1),
Germany; the University Medical Center of Arizona,
Tucson, AZ (n  1); the City of Hope National
Medical Cancer Center, Duarte, CA (n  1); and
Stanford University Medical Center, Stanford, CA
(n  1). Patients had a median age of 34 years (range,
25-49 years) and histories of advanced PNH with a
median interval from symptoms to HCT of 55 months
(range, 32-215 months). Six of the 7 patients had
been treated unsuccessfully with immunosuppressive
drugs—including corticosteroids (n  6), CSP (n 
2), or azathioprine and MMF (n  1)—before HCT
and received a median of 18 units of RBC transfu-
sions (Table 1). Five of the 7 patients had experienced
complications or showed features of PNH known to
be negative, high-risk prognostic factors that lead to
shortened survival. These complications or features
included evolution to pancytopenia (n  1), a history
of thrombosis (n 4), Budd-Chiari syndrome (n 2),
thrombocytopenia at the time of diagnosis (n  1),
and infections (n  3). In 2 patients (nos. 1 and 7),
hemolysis with increasing transfusion requirements
was the indication for HCT. Five patients were con-
sidered to be ineligible for myeloablative conditioning
because of comorbidities and were offered the mini-
mal conditioning protocol. Patient decision was the
reason for transplantation with minimal conditioning
in 2 patients (nos. 1 and 7). The individual study
protocols were approved by the institutional review
boards of the participating institutions, and written,
informed consent was obtained from all patients. Re-
sults were analyzed as of December 15, 2002.
Patient Histories
Patient 1.This 30-year-old patient was admitted in
September 1998 because of syncopal episodes, pancy-
topenia (hemoglobin, 7.6 g/dL; leukocytes, 2.2/nL;
neutrophils, 1.4/nL; and platelets, 60/nL), and recur-
rent abdominal pain. He was found to have severe
hemolytic episodes due to PNH. He was readmitted 3
months later after recurrent hemolytic crises leading
to unconsciousness and increasing pancytopenia. At
that time, 70% of neutrophils, 80% of monocytes,
15% of erythrocytes, and 44% of reticulocytes had
complete GPI-anchored protein deﬁciency. He was
treated with RBC transfusions and according to a
study protocol with CSP 5 mg/kg/d orally and gran-
ulocyte colony-stimulating factor (G-CSF) 5 g/kg/d
subcutaneously. In the absence of a family donor, an
unrelated donor search was initiated, and the patient
was referred to the University of Leipzig. In June
1999, the patient was readmitted to the referring cen-
ter because of Coombs-negative, severe hemolytic cri-
sis. Histology-proven mediastinal sarcoidosis was di-
agnosed. After steroid treatment, the mediastinal mass
disappeared, but the severe hemolytic crises leading to
U. Hegenbart et al.
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fainting episodes continued to recur. He refused con-
ventional unrelated HCT and insisted on a transplan-
tation with reduced conditioning. The case was dis-
cussed at the patient care conference of the Division of
Hematology and Oncology at the University of
Leipzig. The faculty concurred with his eligibility for
the protocol and shared the patient’s concern regard-
ing regimen-related toxicities after conventional
HCT.
Patient 2. The patient was diagnosed with PNH in
1996 and was treated with intermittent prednisone for
repeated bouts of hemolysis until 2000. In January
2000, he presented with abdominal pain, and throm-
bosis of the superior mesenteric vein was diagnosed.
Subsequently, a subdural hematoma with aphasia de-
veloped. Although he recovered most of his neuro-
logic function, he continued to have repeated bouts of
thromboses of the veins of the gastrointestinal tract.
The physicians proposed an unrelated HCT with
nonmyeloablative conditioning given the patient’s
lack of a sibling donor, fragile clinical status (residual
neurologic deﬁcit), age of 49 years, and toxicity asso-
ciated with a myeloablative regimen. In addition, the
patient had a history of an adenoid cystic carcinoma
with extensive resection and reconstructive surgery of
the sinus and oral cavity.
Patient 3. Symptoms of progressive anemia began
in March 1998, and PNH was diagnosed in June 1999.
Progressive hemolysis and thrombocytopenia per-
sisted despite corticosteroid treatment. In June 2000,
the patient developed liver failure due to Budd-Chiari
syndrome; this required urokinase treatment, and the
patient was admitted to the intensive care unit. Allo-
geneic transplantation was considered given his life-
threatening complications. Because of persistent liver
dysfunction, however, standard conditioning for HCT
was contraindicated. After discussion at the patient
care conference and family conferences, the patient
was enrolled on the minimal conditioning protocol,
which was approved by the local ethics committee.
Patient 4.MDS and 5q deletion were diagnosed in
this 40-year-old patient in 1994. She received 26 units
of RBC transfusions and 4 units of platelets. After a
5-year period of transfusion independence, the patient
developed transfusion requirements. She was referred
with pancytopenia (hemoglobin, 4.96 g/dL; leuko-
cytes, 1.9/nL; neutrophils, 0.360/nL; and platelets,
15/nL), severe infections (pneumonia and septicemia),
and recurrent abdominal pain. The patient had severe
Coombs-negative hemolysis, and PNH was diagnosed
by means of ﬂuorescence-activated cell sorter (FACS)
analysis. The bone marrow biopsy showed hypoplasia
Table 1. Characteristics of Patients with PNH and Graft Composition (n  7)
Variable
Patient No.
1 2 3 4 5 6 7
Age (y) 30 49 25 40 34 49 34
Interval, symptoms PNH diagnosis (mo) 1 7 16 68 10 162 156
Therapy of PNH
Corticosteroids Yes Yes Yes No Yes Yes Yes
Cyclosporine Yes No No No No Yes No
Azathioprine, MMF No No No No No Yes No
Blood transfusions
RBC (units) 12 10 >30 14 2 >30 >30
Platelets (units) 0 0 0 6 0 0 0
Risk factors
Pancytopenia No No No Yes No No No
History of thrombosis No Yes Yes No Yes Yes No
Budd-Chiari syndrome No No Yes No No Yes No
Life-threatening hemolysis or infections Yes No No Yes No Yes Yes
Karnofsky score 90 80 90 40 NA 70 80
Blood counts at time of HCT
Hemoglobin (g/dL) 9.1 12.7 9.8 5.9 7.4 7.6 7.6
Leukocytes (per nL) 7.4 7.3 12.0 1.2 6.2 3.1 4.2
Neutrophils (per nL) 6.6 ND 10.2 0.2 3.8 0.7 1.8
Platelets (per nL) 88 201 136 6 147 156 221
Transplantation characteristics
Interval, PNH diagnosis HCT (mo) 24 48 16 20 27 12 59
Transplantation date 10/19/99 7/31/00 11/7/00 11/24/00 4/23/01 6/14/01 11/9/01
Donor Unrelated Unrelated Unrelated Unrelated Related Unrelated Related
Blood group (recipient/donor) A/A A/A B/O A/A O/O A/O O/A
Sex (recipient/donor) M/M M/M F/F F/M F/M F/M M/M
CMV status (recipient/donor) Neg/neg Pos/pos Neg/pos Neg/pos Neg/neg Pos/neg Pos/neg
CD34 cells ( 106/kg infused) 5.6 6.8 4.4 5.3 3.8 7.1 7.8
Stem cell source Blood Blood Blood Blood Blood Blood Blood
ND indicates not done; NA, not applicable; CMV, cytomegalovirus; neg; negative; pos, positive.
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with regeneration. Cytogenetics were normal, and no
dysplasia was noted in the marrow aspirate. HCT was
considered; however, because of increased liver en-
zymes, a creatinine clearance of 56.2 mL/min, multi-
ple pulmonary lesions suggestive of aspergillus on a
chest CT scan, a Karnofsky score of 40, and an in-
creased ferritin of 4204 ng/mL (reference range, 10-
160 ng/mL), a conventional HCT was contraindi-
cated. The minimal conditioning protocol, approved
by the local ethics committee, was offered to the
patient.
Patient 5. This 35-year-old female patient noted
the onset of fatigue in 1998. Dark urine was noted in
October and December 1998, when she sought med-
ical attention. Urinalysis showed blood and rare
RBC. She had a leukocyte count of 3.9/nL, hematocrit
21%, and platelets 107/nL. Bone marrow was hyper-
cellular with normal cytogenetics, and ﬂow cytometry
showed an absence of the GPI-linked proteins CD55
and CD59. She was treated with prednisone, with
some clinical improvement, but developed typical ste-
roid side effects. She also developed superﬁcial lower
extremity thromboses and required transfusion of
RBCs. The patient sought transplantation evaluation
because of her frustration with being chronically ill as
well as the steroid side effects. An HLA-matched
related donor was identiﬁed. However, because of
increased transaminases and hepatic unrest in the liver
biopsy specimen, she was believed to be at increased
risk for severe veno-occlusive disease of the liver.
HCT after minimal conditioning was chosen as the
preferred option.
Patient 6. Aplastic anemia was diagnosed in this
49-year-old patient in 1987 and was treated with pred-
nisolone and, later, CSP. The patient reached remis-
sion in 1992. In 1993, pancytopenia recurred after
CSP withdrawal, and prednisolone and, later, azathio-
prine were administered. Only after CSP treatment
did the blood counts normalize. In 1999, pancytopenia
recurred, and treatment with prednisolone, followed
by CSP, azathioprine, and, eventually, MMF, was ad-
ministered. Hyperthyroidosis and renal insufﬁciency
were diagnosed. In December 2000, after features of
MDS appeared in the bone marrow aspirate, the pa-
tient was referred to the University of Leipzig for
further workup. The bone marrow aspirate and biopsy
were normocellular, without evidence of severe aplas-
tic anemia or MDS, and cytogenetics were normal.
PNH was diagnosed on the basis of hemolysis and
deﬁciency of CD55 expression on neutrophils (60%),
monocytes (66.5%), and erythrocytes (46.7%) in the
FACS analysis. In addition, CD59 deﬁciency was
shown on 42.2% of granulocytes, 19.1% of lympho-
cytes, and 41.1% of erythrocytes. Thyroidectomy was
performed in December 2000. Joint pain, febrile epi-
sodes, intercurrent hemolysis, and abdominal pain
persisted during the following months. In April 2001,
pancytopenia and massive liver enlargement after liver
vein thrombosis were diagnosed. Despite heparin
treatment, hepatosplenomegaly increased and ascites
developed. Lung inﬁltration suggestive of aspergillus
was diagnosed in May 2001, and treatment with ap-
propriate therapy was begun. HCT was considered,
but because of the liver dysfunction with Budd-Chiari
syndrome, history of liver vein thrombosis, and pre-
sumed pulmonary aspergillus, she was considered in-
eligible for conventional conditioning. The case was
discussed at the patient care conference, and the fac-
ulty concurred that she was eligible for the protocol
with reduced-intensity conditioning.
Patient 7. PNH was diagnosed in this 29-year-old
man after an approximately 13-year history of episodic
abdominal discomfort. His diagnosis of PNH was
conﬁrmed with bone marrow ﬂow cytometry during
an episode of severe abdominal pain that required
hospital admission. The patient was maintained on 5
to 20 mg of prednisone every other day, as well as
anticoagulation to limit the episodes of abdominal
pain and hemolysis. He presented for HCT evaluation
approximately 3 years after his PNH diagnosis, and an
HLA-matched sibling donor was identiﬁed. At the
time of HCT, at 35 years of age, his RBC transfusion
requirements had been escalating despite continued
prednisone therapy; he received RBC transfusions ev-
ery 3 weeks to maintain a hemoglobin of 10 g/dL. The
patient received the minimal-conditioning regimen
after thoughtful discussion with him and his family
regarding the known risks and beneﬁts of the standard
myeloablative and nonmyeloablative conditioning.
Collection of Hematopoietic Cells and
Transplantation Procedure
HCTs were performed with G-CSF mobilized
hematopoietic cells from the peripheral blood (G-
PBMC) of related (n  2) and unrelated (n  5)
donors matched by serologic techniques for HLA-A,
-B, and -C and, at the allele level, for the HLA-DRB1
and -DQB1 loci. All unrelated hematopoietic cell col-
lections were coordinated through donor registries
and collected by following the unrelated donor regis-
try protocol. The donors received 10 g/kg/d of G-
CSF subcutaneously on days 5 through 1. Leuka-
phereses of 12 L of blood volume were performed on
days 1 and 0. Both G-PBMC collections were com-
bined, transported in a cold pack to the transplant
center, and transfused after TBI on day 0.
Family donors of patients 5 and 7 received G-CSF
16 g/kg/d by a subcutaneous daily injection for 5
consecutive days from day 4 to day 0. G-PBMC
were collected by a vein-to-vein technique by using a
standard apheresis machine processing up to 16 L of
whole blood in the afternoon of day 1 and stored in
the refrigerator at 4°C overnight. A second collection
U. Hegenbart et al.
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was performed the following afternoon, and both col-
lections were transfused on day 0.
Patients with ABO incompatibilities (n  3) re-
ceived either RBC-depleted G-PBMC (patient 7) or
G-PBMC resuspended in AB plasma (patients 3 and
6). The grafts contained a median of 5.6 106 (range,
3.8-7.8  106) CD34 cells per kilogram of body
weight and were infused without further manipula-
tion.
Conditioning Regimen and Postgrafting
Immunosuppression
Fludarabine 30 mg/m2/d intravenously was given
from days 4 to 2, and 2 Gy of TBI was delivered
from linear accelerators at a dose rate of 7 cGy/min on
day 0. Immunosuppressive therapy with oral CSP,
6.25 mg/kg twice a day, was started on day 3, and
MMF, 15 mg/kg twice a day, was started 4 to 6 hours
after HCT on day 0. Intravenous formulations of CSP
and MMF were administered if patients were not able
to tolerate oral medications. In patients receiving un-
related HCT, MMF was scheduled to be tapered
between days 40 and 96 and CSP at day 180 over 80
days. In patients receiving related HCT (patients 5
and 7), MMF was discontinued on day 27, and CSP
was scheduled to taper from day 56 to day 180 after
HCT.
Supportive Care
Standard prophylaxis was used against Pneumocystis
carinii, fungal, and cytomegalovirus infections [21,22].
Acute and chronic GVHD were graded as previously
described [23,24]. Treatment of acute GVHD grade
II and of extensive chronic GVHD consisted of sys-
temic immunosuppression and antibiotic prophylaxis
for Pneumocystis carinii and pneumococcal infections
[25].
Analysis of Donor Hematopoietic Chimerisms
The degrees of donor chimerism among T cells,
granulocytes, and nucleated cells in the peripheral
blood were assessed at days 28, 56, 84, 180, and 365
after HCT and, whenever possible, in the bone mar-
row. T cells and granulocytes were sorted by FACS
and analyzed either by using ﬂuorescence in situ hy-
bridization to detect X and Y chromosomes for sex-
mismatched transplants or by using polymerase chain
reaction–based analysis of polymorphic microsatellite
regions for sex-matched transplants [26].
Analysis of Disease Responses
Ham’s test and FACS determination of CD55 and
CD59 were performed on days 28, 56, 84,
180, and 365 after HCT, as described previously
[27].
RESULTS
Regimen-Related Toxicities and Infections
Table 2 summarizes the patients’ posttransplanta-
tion courses. None of the patients developed new-
onset alopecia. Mild to moderate nausea and vomiting
were common. One patient developed bacteremia (co-
agulase-negative staphylococci), and 1 patient devel-
oped fever of unknown origin, both of which resolved
under treatment with antibiotics. One patient (patient
4) presented with pneumonia before HCT, which
Table 2. Toxicity, Engraftment Characteristics, and Outcome after HCT for PNH (n  7)
Variable
Patient No.
1 2 3 4 5 6 7
Nonhematologic toxicity*
Gastrointestinal 2 1 1 1 1 3 2
Renal 1 0 0 1 0 2 0
Hepatic 1 3 2 0 1 3 0
Engraftment and transfusion requirements
Days neutrophils <0.5/nL 9 0 0 12 0 11 0
Days platelets <20/nL 0 0 0 8 0 5 0
RBC transfusions (no. of units) 2 0 2 6 2 18 4
Platelet transfusions (no. of units) 3 0 0 6 0 14 0
GVHD
Acute (grade) II II II 0 II II 0
Chronic No Extensive Extensive Subacute/chronic Limited NA Subacute/chronic
Survival (mon) >38 †12.5 >25 †14 >20 †2 >13
Causes of death Infection Bleeding after
liver biopsy for
chronic GVHD
Pancreatitis,
multiorgan
failure
*From day 0 to 100 after transplantation; common toxicity criteria grades.
†Death.
NA indicates not applicable.
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resolved after engraftment and antibiotic therapy.
Concomitant Epstein-Barr virus and cytomegalovirus
reactivations were diagnosed in another patient (pa-
tient 6). Seizures of unknown origin were observed in
the same patient. Other nonhematologic toxicities in-
cluded the appearance (n  1; patient 2) or worsening
of Budd-Chiari syndrome (n  2; patients 3 and 6)
shortly after HCT. In all affected patients, the Budd-
Chiari syndrome eventually improved, with complete
resolution in 2 patients. In 1 patient (no. 6), Budd-
Chiari Syndrome was detectable on histology at au-
topsy.
Peripheral Blood Cell Changes, Allogeneic
Engraftment, and GVHD
Neutrophils 0.500/nL were encountered in 3 of
the 7 patients immediately after HCT. The median
duration of neutrophils 0.500/nL was 4.5 days
(range, 0-12 days), and that of platelets 20/nL was 0
days (range, 0-8 days). Platelet transfusions were re-
quired in 2 patients and given to a further patient
(patient 1) prophylactically because of an invasive di-
agnostic procedure (colonoscopy). RBC transfusions
were necessary in 6 patients. One patient (patient 4)
developed immune thrombocytopenia 6 months after
HCT and was treated with splenectomy after cortico-
steroid and intravenous immunoglobulin treatment
failed.
All patients achieved durable engraftment despite
their transfusion histories. Figure 1 illustrates the per-
centages of donor-derived nucleated cells and CD3
T lymphocytes in the peripheral blood at set time
points after HCT. On day 28 after HCT, the me-
dian percentage of donor nucleated cells was 96.5%
(range, 90%-100%) and of CD3 T cells was 77%
(range, 53%-96%). The CD3 T-cell donor chimer-
ism increased to a median of 91% (range, 76%-100%)
on day 180 and reached 100% in the 3 patients
studied on day 365 after HCT. One patient (no. 3)
had an intermittent decrease in donor T-cell chimer-
ism to 13% on day 86 (38% on day 101), which
reverted to complete donor chimerism after reduction
of immunosuppression and an episode of GVHD on
day 161.
Five of 7 patients developed grade II acute GVHD
at a median of 37 days (range, 13-138 days) after
HCT. Acute GVHD appeared in most patients at the
time of MMF or CSP taper. The acute GVHD was
treated with systemic steroids in 5 patients and ste-
roids in combination with psoralen-ultraviolet light
administration in 1 patient (no. 1). Acute GVHD
resolved completely in 1 patient (no. 1), whereas 1
patient (no. 6) died during therapy of acute GVHD
from complications of acute pancreatitis and multior-
gan failure. In 3 patients, acute GVHD progressed to
chronic GVHD, which was treated with CSP (patient
5); corticosteroids and MMF (patient 2); and CSP,
MMF, and inhaled steroids for bronchiolitis obliter-
ans (patient 3). One patient died from an acute infec-
tion (patient 2), and another patient (no. 3) remained
on immunosuppression. Two patients developed sub-
acute chronic, de novo GVHD at the time of CSP
taper or withdrawal. One patient (no. 7) had devel-
oped subacute/chronic GVHD of the gut 4 months
after HCT, which resolved after treatment with ther-
apeutic doses of CSP and corticosteroids. Patient 4
Figure 1. Percentage donor chimerism among peripheral blood cells. Median percentages of donor nucleated cells and CD3 cells (T
lymphocytes) are shown for the ﬁrst 360 days after HCT. The numbers of patients analyzed at days 28, 56, 84, 180, and 365 were, respectively,
6, 6, 5, 5, and 2 for nucleated cells and 7, 5, 6, 5, and 3 for T cells.
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had liver chronic GVHD 14 months after HCT and
died of hemorrhage after a liver biopsy while being
treated with methylprednisolone and OKT 3.
Causes of Death
Three patients died: 1 (patient 6) of necrotizing
pancreatitis of unknown cause and multiorgan failure
(day 62), 1 (patient 2) of pseudomonas infection
during treatment of chronic GVHD (day 380), and
1 (patient 4) of hemorrhage after liver biopsy with
subacute/chronic liver GVHD (day 406).
Disease Responses
In all patients, the PNH clones were undetectable
by FACS sorting by day 56 after HCT and remained
undetectable during the observation period (Figure 2).
All patients, including those who presented with pan-
cytopenia or hemolysis at the time of HCT, attained
normal peripheral blood counts and haptoglobin val-
ues and were transfusion independent after HCT.
The 4 patients alive have normal blood counts and a
Karnofsky score of 100 and are working full-time.
One of them is expecting her third child in September
2003.
DISCUSSION
Allogeneic HCT offers the only current cure for
PNH. However, expectations for cure must be
weighed against the risks of regimen- and transplant-
related morbidity and mortality. Until now, HCT has
been performed exclusively with the use of intensive
conditioning regimens, often including high-dose
busulfan, cyclophosphamide, and antithymocyte glob-
ulin for HLA-matched sibling grafts and high-dose
TBI and cyclophosphamide for unrelated grafts. In
large part because of concerns about regimen-related
toxicities and, to a lesser extent, GVHD, the decisions
to transplant have generally been postponed until the
advent of life-threatening complications such as severe
hemolytic crises with increasing transfusion require-
ments that do not respond to immunosuppression;
recurrent thromboses; or Budd-Chiari syndrome.
These complications, however, have precluded the use
of high-dose conditioning regimens because of the
increased likelihood of regimen-related mortality.
Life-threatening complications occurred before HCT
in 5 of the 7 current patients, who, by necessity,
became candidates for nonmyeloablative condition-
ing. The remaining 2 patients, in whom allogeneic
HCT was also clearly indicated, made a personal
choice for nonmyeloablative over ablative condition-
ing.
Despite adverse risk factors in 5 of the 7 current
patients and preceding multiple transfusions in all 7,
the regimen of ﬂudarabine 90 mg/m2 and 2 Gy of TBI
combined with postgrafting immunosuppression of
MMF and CSP was both well tolerated and effective.
Uniform and durable engraftment of G-PBMC from
related and unrelated donors was achieved, and sus-
tained remissions of the underlying disease were in-
duced. No graft rejections were observed in the 7
patients. The uniform sustained engraftment in the
current 7 multiply-transfused patients stands in sharp
contrast to the transient engraftment in 7 transfused
children with hemoglobinopathies treated with a sim-
ilar HCT regimen [28]. The reasons for this differ-
ence are unclear. GVHD, however, has remained a
serious problem. Five patients developed grade II
acute GVHD. All 5 patients required systemic ther-
apy, and 1 of the 5 died from complications related to
acute pancreatitis within 2 months of HCT. Further-
more, 4 patients developed extensive chronic GVHD,
which was progressive in 2 patients and de novo in 2
others during CSP withdrawal. One of the 2 patients
with de novo onset had resolution of subacute/chronic
GVHD after immunosuppressive therapy, whereas
the other died from hemorrhage after a liver biopsy 14
months after HCT. One of the 2 patients with pro-
gressive chronic GVHD died from infection 12
months after HCT. Clearly, improved GVHD con-
trol remains a critical future research objective. Opti-
mizing immunosuppression by prolonging CSP ther-
apy and dose-adapted MMF therapy might be a
promising way of reducing GVHD [29].
Other investigators have described substantial
rates of transplant-related mortality after conventional
HCT for PNH. The largest series, reported by Saso
et al. [6], described 57 patients who underwent trans-
plantation after myeloablative conditioning from re-
lated (n 50) and unrelated (n 7) donors. Nineteen
(33.3%) of the 57 patients died within the ﬁrst 4
months from graft failure (35%), infection (15%),
GVHD (15%), bleeding (5%), and interstitial pneu-
monitis or acute respiratory distress syndrome (30%).
Figure 2. Percentage of CD55 or CD59 granulocytes. Median
percentages of granulocytes are shown before and after HCT
(n  4).
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Long-term survival was 56% after related and 14%
after unrelated HCT. Bemba et al. [7] described 6
deaths related to GVHD, infections, or both among
14 patients given conventional HCT. Of note, these
investigators excluded patients with a history of
thrombosis. Prognostic factors for improved out-
comes were neutrophils 1.0/nL and a hemoglobin
level of 9 g/dL before HCT. Woodard et al. [8]
performed unrelated HCT with T-cell–depleted
grafts in 3 patients, all of whom experienced signiﬁ-
cant but short-lasting transplant-related complica-
tions; all 3 survived with sustained grafts.
In conclusion, the complete hematologic reconsti-
tution by donor cells, the disappearance of disease
symptoms, and long-term survival after allogeneic
HCT in patients with long-lasting and high-risk PNH
disease are encouraging. This report suggests that
minimal-conditioning HCT should be considered in
those patients with PNH who have comorbidities that
preclude conventional myeloablative conditioning.
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